Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASTX-660 + Decitabine and Cedazuridine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASTX-660 | ASTX660|ASTX 660|Tolinapant | SMAC Mimetic 8 | ASTX-660 is a SMAC mimetic that inhibits cIAP and XIAP, potentially resulting in tumor cell death (Cancer Res 2016;76(14 Suppl):Abstract nr 1287, PMID: 31900279). | |
| Decitabine and Cedazuridine | Inqovi | ASTX-727|ASTX 727|ASTX727 | Chemotherapy - Antimetabolite 14 | Inqovi (decitabine and cedazuridine) is a combination of decitabine and cedazuridine, which may inhibit proliferation of tumor cells (PMID: 30926081). Inqovi (decitabine and cedazuridine) is an FDA approved chemotherapy agent (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04155580 | Phase I | ASTX-660 ASTX-660 + Decitabine and Cedazuridine | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Terminated | USA | 0 |